Surmodics Inc Stock

$28.81

0.96% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US8688731004

Symbol

SRDX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Surmodics Inc Stock price

$28.81

-14.56 33.57% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.28 0.96%

ISIN

US8688731004

Symbol

SRDX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$412.0m

Enterprise Value

$410.4m

Net debt

$-1.5m

Cash

$31.2m

Shares outstanding

14.3m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

3.39 | 3.51

EV/Sales

3.38 | 3.50

EV/FCF

negative

P/B

3.74

Financial Health

Equity Ratio

66.59%

Return on Equity

-9.71%

ROCE

-2.66%

ROIC

-4.22%

Debt/Equity

0.27

Financials (TTM | estimate)

Revenue

$121.6m | $117.4m

EBITDA

$-500.0k | $8.8m

EBIT

$-4.0m

Net Income

$-19.9m | $-8.1m

Free Cash Flow

$-7.4m

Growth (TTM | estimate)

Revenue

-14.96% | -6.86%

EBITDA

-102.19% | 463.27%

EBIT

-120.59%

Net Income

-247.00% | 29.98%

Free Cash Flow

-132.98%

Margin (TTM | estimate)

Gross

73.37%

EBITDA

-0.41% | 7.48%

EBIT

-3.27%

Net

-16.34% | -6.88%

Free Cash Flow

-6.12%

EPS

$-1.40

FCF per Share

$-0.52

Short interest

2.92%

Employees

389.00

Rev per Employee

$320.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Surmodics Inc Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Surmodics Inc forecast:

6x Buy

67%

3x Hold

33%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Surmodics Inc forecast:

Buy

67%

Hold

33%

Analyst Estimates with Stock Price Targets

Financial data from Surmodics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	122 122	15% 15% 100%
- Direct Costs	32 32	8% 8% 27%
Gross Profit	89 89	21% 21% 73%
- Selling and Administrative Expenses	53 53	3% 3% 44%
- Research and Development Expense	37 37	8% 8% 30%
EBITDA	-0.50 -0.50	102% 102% 0%
- Depreciation and Amortization	3.47 3.47	1% 1% 3%
EBIT (Operating Income) EBIT	-3.97 -3.97	121% 121% -3%
Net Profit	-20 -20	247% 247% -16%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Surmodics Inc Stock News

Neutral

Business Wire

●

about 2 months ago

Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of ...

Neutral

Business Wire

●

2 months ago

Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast a...

Neutral

Business Wire

●

2 months ago

Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients...

More Surmodics Inc News

Company Profile

SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Head office	United States
CEO	Gary Maharaj
Employees	389
Founded	1979
Website	www.surmodics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now